Integra LifeSciences (IART) to Release Earnings on Tuesday

Integra LifeSciences (NASDAQ:IART) is anticipated to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Integra LifeSciences to post earnings of $0.86 per share and revenue of $445.15 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $21.13 on Friday. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences has a 1 year low of $16.81 and a 1 year high of $45.11. The company has a market cap of $1.63 billion, a PE ratio of -234.75, a PEG ratio of 0.73 and a beta of 1.17. The company’s 50-day moving average is $23.71 and its two-hundred day moving average is $21.81.

Insider Buying and Selling at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IART. Citigroup increased their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley initiated coverage on Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price for the company. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.